What is HC Wainwright's Estimate for MIST FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Milestone Pharmaceuticals to ($0.70) from ($0.71) and maintains a Buy rating with an $8.00 price objective.
• HC Wainwright projects steady improvement thereafter, forecasting ($0.61) for FY2027, $0.53 for FY2028 and $1.03 for FY2029.
• Milestone recently topped quarterly expectations (reported ($0.12) vs. estimate ($0.17)), and analyst sentiment has shifted toward Buy with a consensus target price of $8.00.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report issued on Monday, December 15th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.70) for the year, up from their previous estimate of ($0.71). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' FY2027 earnings at ($0.61) EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $1.03 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05.

A number of other analysts have also recently commented on MIST. Cowen raised Milestone Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Monday. Wall Street Zen cut Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday. TD Cowen raised Milestone Pharmaceuticals from a "hold" rating to a "buy" rating and set a $8.00 target price on the stock in a research note on Monday. Weiss Ratings restated a "sell (d-)" rating on shares of Milestone Pharmaceuticals in a report on Monday. Finally, Wells Fargo & Company upped their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an "overweight" rating in a research note on Tuesday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Milestone Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $2.20 on Wednesday. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The firm's 50-day simple moving average is $2.19 and its two-hundred day simple moving average is $1.92. The stock has a market cap of $187.37 million, a PE ratio of -2.68 and a beta of 0.41. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MIST. Millennium Management LLC purchased a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at $803,000. Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals during the 3rd quarter valued at about $1,333,000. Bank of America Corp DE boosted its holdings in shares of Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company's stock valued at $32,000 after acquiring an additional 16,044 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Milestone Pharmaceuticals in the third quarter worth approximately $6,444,000. Finally, Two Sigma Investments LP bought a new stake in shares of Milestone Pharmaceuticals in the third quarter worth approximately $1,333,000. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.